Apr 29, 2026
Apr 29, 2026
Apr 29, 2026
Apr 29, 2026
Apr 29, 2026
Apr 29, 2026
Apr 29, 2026
Apr 29, 2026
With the spotlight on GLP-1 weight-loss drugs, Eli Lilly and Viking Therapeutics are key players. But are investors ready to hold for long-term gains?